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Amyotrophic lateral sclerosis is a progressive neurodegenerative disease of motor neurons. About 25 genes have been veriﬁed as
relevant to the disease process, with rare and common variation implicated. We used next generation sequencing and repeat sizing
to comprehensively assay genetic variation in a panel of known amyotrophic lateral sclerosis genes in 1126 patient samples and
613 controls. About 10% of patients were predicted to carry a pathological expansion of the C9orf72 gene. We found an increased
burden of rare variants in patients within the untranslated regions of known disease-causing genes, driven by SOD1, TARDBP,
FUS, VCP, OPTN and UBQLN2. We found 11 patients (1%) carried more than one pathogenic variant (P = 0.001) consistent with
an oligogenic basis of amyotrophic lateral sclerosis. These ﬁndings show that the genetic architecture of amyotrophic lateral
sclerosis is complex and that variation in the regulatory regions of associated genes may be important in disease pathogenesis.
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Introduction
Amyotrophic lateral sclerosis (ALS) is a fatal, neurodegenera-
tive disorder with a life expectancy of 3–5 years from symp-
tom onset. Presentation is with weakness of voluntary
muscles, representing degeneration of the upper and lower
motor neurons. The incidence of ALS is approximately
2 per 100000 person–years with a slightly higher proportion
of males (Logroscino et al., 2010). About 15% have concomi-
tant frontotemporal dementia (FTD) and up to 50% may
have subtle cognitive impairment (Abrahams et al., 2014).
The complexity of the molecular mechanisms implicated
in ALS is paralleled by multifaceted genetics that are still
not fully understood despite extensive research (Al-Chalabi
and Hardiman, 2013; Morgan and Orrell, 2016). To ad-
dress this issue, there has been a move towards next-gen-
eration sequencing (NGS) as a high-throughput, relatively
inexpensive tool to uncover the genetic architecture of ALS
and other heterogeneous neurological diseases, including
Charcot–Marie–Tooth disease, dementia, ataxia and
Parkinson’s disease (Johnson et al., 2010; Mencacci et al.,
2014; Cady et al., 2015; Cirulli et al., 2015; van Rheenen
et al., 2016).
About 5–10% of ALS is considered familial (familial
ALS), which may be an underestimate depending on the
deﬁnition used (Byrne et al., 2012), and there is extensive
evidence that the distinction between familial and sporadic
ALS is not clear-cut (Al-Chalabi and Lewis, 2011). Over
100 genes have been implicated in ALS to varying degrees
(Abel et al., 2012; http://alsod.iop.kcl.ac.uk), with 25 of
these having been replicated in subsequent studies. The four
most important ALS genes by frequency are SOD1,
TARDBP/TDP-43, C9orf72 and FUS. Variants in these
genes are more likely to be of large effect, and carrying
the genotype greatly increases the probability of ALS; in
other words, these variants show moderate to high pene-
trance. Gene variants of low penetrance are also of interest,
even though they only increase risk a little for any individ-
ual, as the overall variance in genetic risk explained is high,
and such genes contribute to our understanding of the
pathway to ALS. In at least some cases, ALS is oligogenic,
with affected individuals carrying more than one rare vari-
ant implicated in ALS (van Blitterswijk et al., 2012; Cady
et al., 2015). If a signiﬁcant number of cases in ALS are
indeed caused by more than one risk variant, this has im-
plications for genetic counselling and treatment.
We therefore aimed to explore the genetics of ALS in a
cohort of 1126 patients using a speciﬁc ALS-gene panel for
NGS.
Materials and methods
Patients
A total of 1126 cases and 613 controls of European ancestry
were used as part of this study. This was composed of 131
individuals with familial ALS (64 female, 67 male) and 995
with sporadic ALS (428 female, 567 male). The average age of
onset was 56 years for familial ALS (range 24–85) and 61 for
sporadic ALS (range 25–88). Control samples were composed
of 232 females and 381 males. These clinical data are pre-
sented in Supplementary Table 1. Averaged across loci,
13 cases and 15 controls failed to sequence across some of
the target genome. Three hundred and seventeen patients did
not have complete C9orf72 data because of insufﬁcient DNA.
Patient samples were obtained predominantly from the UK
National DNA Bank for Motor Neuron Disease (MND)
Research (Smith et al., 2015) as well as from University
College London and Partners (UCLP) MND clinics. A small
subset (n = 95) of these samples overlap with our previous
proof-of-principle publication and were included in this study
to increase the power to detect mutation burden (Morgan
et al., 2015). Control samples were either sequenced using
MiSeq technology (see below), whole-exome sequencing or
both. They were selected based on their ethnicity, age (over
60 years old) and whether they were free from any neuro-
logical disorder. Additionally, subjects were excluded from
the study if they had a ﬁrst-degree relative with a neurological
disorder including Alzheimer’s disease, ALS, ataxia, autism,
bipolar disorder, cerebrovascular disease, dementia, dystonia,
Parkinson’s disease and schizophrenia.
Next-generation sequencing
An ALS-speciﬁc gene panel was designed for use on the
Illumina MiSeq platform by means of the Illumina TruSeq
Custom Amplicon Assay. This uses PCR amplicon-based
target enrichment, and screens for variants across 23 genes
that were selected based on their association with ALS, so
that all the chief causal genes were included as well as several
risk factors and a selection of variants with an uncertain rela-
tionship to ALS, either through a lack of evidence or through
the gene more commonly causing a related disease. The panel
included exons and ﬂanking regions for ALS2, ANG,
CHMP2B, DAO, DCTN1, FIG4, FUS, NEFH, OPTN,
PFN1, PON1, PON2, PON3, PRPH, SETX, SOD1,
SQSTM1, TARDBP, TREM2, UBQLN2, VAPB, VCP and
VEGFA. The following genes were also extensively covered
in both 5’ and 3’ untranslated regions (UTRs): three were se-
lected because they are regarded as major ALS genes (SOD1,
TARDBP, FUS) and three because the design of the assay
made sequencing through the untranslated region simple to
achieve (OPTN, VCP, UBQLN2; Supplementary Table 2).
This study was initiated before the discovery of the ALS
genes C21orf2, CHCHD10, MATR3, NEK1, TBK1 and
TUBA4A.
Bioinformatic analysis
The raw FASTQ ﬁles from the Illumina MiSeq were aligned to
the human reference genome build 19 (GRCh37) using
Novoalign v3 hg19 (for transcripts see Supplementary Table
3), and variants were called using SAMtools v0.1.18 and
GATK v3.3. Low quality variants were ﬁltered as described
previously (Morgan et al., 2015). Annotation was performed
using ANNOVAR Nov2014 (Wang et al., 2010) and Variant
Effect Predictor (VEP v84) tools (McLaren et al., 2010) and
compared against the ExAC database of genetic variants
2 | BRAIN 2017: Page 2 of 8 S. Morgan et al.
(http://exac.broadinstitute.org/), 1000 Genomes (www.
1000genomes.org), ESP6500 (evs.gs.washington.edu), UK10K
(http://www.uk10k.org/) and cg69 (www.completegenomics.
com/public-data/69-Genomes) to remove common variants
[minor allele frequency (MAF)41% of the European-derived
population]. Any locus with signiﬁcant missingness between
cases and controls was excluded using PLINK v1.09 (Purcell
et al., 2007). An in-house coverage analysis software
(CovCheck) determined that 92% of the desired regions
were covered by at least 10 reads. The data were independ-
ently analysed by two separate groups to ensure different
methods produced matching results, and every locus was visu-
ally inspected to guarantee high-quality data. Variants called
with 10–20 reads were ﬂagged to be visually inspected to
remove false positives. A selection of these were checked
using Sanger sequencing to ensure calling was correct.
Repeat expansions
A major drawback of NGS is its inability to reliably assay
variation represented by repeats such as those in C9orf72
and ATXN2. Therefore, repeat-primed PCR was used to
detect the expansion mutation in C9orf72 and standard frag-
ment length analysis for the microsatellite repeat in ATXN2.
The primers and methods used for C9orf72 and ATXN2
repeat detection have been previously described (Pulst et al.,
1996; DeJesus-Hernandez et al., 2011).
Statistical analysis
Because rare variation is too infrequent to test statistically in a
sample of this size, we used a region-based test comparing the
rare-variant burden in cases and controls in the form of the
SNP (single nucleotide polymorphism)-set sequence kernel as-
sociation test (SKAT v1.1.2; Wu et al., 2011; Fig. 1). We
included intronic, exonic, synonymous, coding, and known
causal variants only if they were novel or with a
MAF50.01 and were of high-quality with no bias in the
proportion of missing data between cases and controls.
Comparing controls post-ﬁltering, which had been examined
using whole-exome and MiSeq-targeted sequencing, revealed
differences only in the calling of indels of two or more nucleo-
tides and not in any of the SNPs. We therefore used whole-
exome sequenced samples as controls for SNP data only and
did not include indels of two or more nucleotides in the ana-
lysis. The genes C9orf72, ATXN2, PON1–3 and VEGFA were
not included in SKAT analysis due to the nature of their as-
sociation with the disease (repeat expansions or common vari-
ation), but were instead analysed separately as described
below. Sex was used as a covariate. A total of ﬁve tests
were carried out; adjusted P-values are reported using the for-
mula:
B ¼ 1 ð1 PÞn ð1Þ
Where P is the critical P-value obtained in the test, n is the
number of tests completed and B is the Bonferroni corrected
P-value.
To examine a potential oligogenic basis of ALS, variants
were analysed using a binomial test in R v3.2.3 as described
previously (van Blitterswijk et al., 2012; Fig. 1). Heterozygous
and homozygous variants were treated as a single event and
tested using the binomial distribution by the formula:
f ðxÞ ¼
 n
x

pxð1 pÞðnxÞ where x ¼ 0;1; 2; . . . ;n ð2Þ
Where f(x) is the probability of observing more than one
rare variant in a single individual, n is the total number of
patients, x the number of people carrying more than one vari-
ant, and p is the expected frequency of rare variation derived
from the averaged frequency of rare variation observed in
cases and controls.
We performed this test twice, ﬁrst on reported ALS-variants
only and then on variation found in C9orf72, SOD1,
TARDBP, FUS, ANG, ALS2, VCP, OPTN, NEFH and
UBQLN2 where we included all rare (MAF50.01), exonic,
coding variation in these genes (excluding C9orf72 where only
repeat expansions were included). These 10 genes were selected
based on those previously tested by van Blitterswijk et al.
(2012) in addition to those we believed to be of importance
to the disease. Reported P-values were corrected for two tests.
For variants in the genes PON1–3 and VEGFA, association
with ALS is with common variation, and so these loci were
selected out of the data and ﬁltered for variants present in
dbSNP (Sherry et al., 2001; Fig. 1). Chi-squared SNP-based
association tests in cases versus controls were performed using
PLINK for these 20 loci and corrected for each iteration.
Results
We performed NGS on 1126 cases and 613 controls that
identiﬁed, on average, 31 variants per individual passing
quality control ﬁlters. Findings are presented in Table 1.
Variant interpretation
One of the major difﬁculties in NGS data is how to inter-
pret the pathogenicity of variants, especially those that are
Figure 1 Simplified flowchart describing the steps taken
from sample to result in this study.
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novel or extremely rare. We found 906 alterations that
were deﬁned as potentially pathogenic, of which 225
were exonic and 55 were previously published as associated
with ALS (48 variants) or another disease. However, some
of these variants were also found in the control cohort
(Table 1). We therefore deﬁned variants as potentially
pathogenic for ALS if they were published previously in
more than one study and not found in control cohorts.
Table 1 Previously published variants in ALS or other diseases that have been found in the current study in either
patients or controls
Chromo-
some
Base pair Gene 1000 g UK10K ExAC dbSNP137 PhyloP SIFT PolyPhen2 LRT Exon Nucleotide
change
Amino
acid
change
Patients,
n
Controls,
n
1 11076931 TARDBP . 0.00052 2.11  104 rs80356715 C B B D 3 C269T A90V 2 1
1 11082325 TARDBP . . 8.13  106 rs80356719 C B B D 6 G859A G287S 2 0
1 11082428 TARDBP . . . . C D B D 6 C962T A321V 1 0
1 11082475 TARDBP . . . rs80356730 C B D D 6 A1009G M337V 1 0
1 11082509 TARDBP . . . . C D P D 6 G1043T G348V 1 0
1 11082588 TARDBP . . . . N NA NA D 6 T1122G Y374X 1 0
1 11082598 TARDBP . . . . C D B D 6 A1132G N378D 2 0
2 74588717 DCTN1 0.0005 0.0047 3.11  103 rs72466496 C D B N 32 C3746T T1249I 0 5
2 74594023 DCTN1 . 0.00078 1.95  104 rs121909344 C D D N 21 C2353T R785W 1 1
2 202626437 ALS2 0.02 0.026 0.025 rs3219154 N B B N 4 A280G I94V 0 33
3 87289899 CHMP2B . 0.00052 1.22  104 rs63750818 N B B N 2 A85G I29V 2 2
3 87294943 CHMP2B . 0.00026 4.07  105 rs200792883 C D D D 3 G206A R69Q 1 0
3 87294985 CHMP2B . . . . C B D D 3 C248T T83I 0 1
5 179251013 SQSTM1 . . 2.20  104 rs145056421 N B B N 3 G457A V153I 0 1
5 179252184 SQSTM1 0.0032 0.0018 2.42  103 rs11548633 C B D D 5 A712G K238E 11 4
5 179263445 SQSTM1 0.0046 0.0021 8.78  104 rs104893941 C D P N 8 C1175T P392L 5 2
6 41129105 TREM2 0.03 0.0023 0.012 rs2234253 C D D D 2 C287A T96K 0 1
6 41129207 TREM2 0.01 0.0088 8.25  103 rs143332484 N B B N 2 G185A R62H 0 10
6 41129252 TREM2 0.0027 0.0021 2.07  103 rs75932628 C B D N 2 G140A R47H 7 4
6 110036336 FIG4 0.0009 0.0031 9.68  104 rs121908287 C D D D 2 T122C I41T 3 5
9 35066777 VCP . . 8.95  105 . C B B D 4 A340G I114V 1 0
9 35068298 VCP 0.0009 0.00052 5.37  104 rs140913250 C B B D 2 A79G I27V 0 1
9 135140020 SETX 0.0027 0.0078 3.40  103 rs151117904 N D B N 26 T7640C I2547T 12 8
9 135204004 SETX 0.0018 . 5.77  104 rs149546633 N D B N 10 A2981G D994G 0 1
9 135204010 SETX 0.01 0.013 0.015 rs61742937 N D B N 10 A2975G K992R 0 16
9 135224757 SETX 0.01 0.0075 9.04  103 rs79740039 N D B N 3 G59A R20H 0 13
10 13152400 OPTN 0.07 0.033 0.045 rs11258194 N B B N 5 T293A M98K 55 33
10 13178802 OPTN . . . . C D D N 16 A1670G K557R 0 1
12 49689009 PRPH 0.02 0.0068 0.014 rs57451017 C D P N 1 G26A R9Q 0 12
12 49690798 PRPH 0.03 0.016 0.022 rs62636520 C B B N 4 G829A A277T 0 20
14 21161845 ANG 0.0005 0.0031 1.42  103 rs121909536 N D B U 2 A122T K41I 0 2
14 21161973 ANG 0.01 . 1.55  103 rs17560 N B B U 2 A250G K84E 1 0
16 31201719 FUS 0.0009 . 6.51  105 rs186547381 C D D D 12 C1292T P431L 1 0
16 31202410 FUS . . . . C D D D 14 G1520A G507D 1 0
16 31202739 FUS . . . rs121909670 N D D D 15 C1561T R521C 1 0
16 31202740 FUS . . . rs121909671 N D D D 15 G1562A R521H 2 0
16 31202740 FUS . . . . N D D D 15 G1562T R521L 1 0
17 4849268 PFN1 0.0005 . 4.15  104 rs140547520 C D D D 3 A350G E117G 1 1
20 57014075 VAPB 0.0009 0.0026 1.34  103 rs146459055 C B B D 4 T390G D130E 0 1
20 57016076 VAPB 0.0018 0.0013 1.35  103 rs143144050 C B P D 5 G510A M170I 7 1
20 57016117 VAPB . 0.0005 . rs145483046 C B B N 5 G551A R184Q 1 0
21 33032107 SOD1 . . . . N D B N 1 C25G L9V 1 0
21 33038821 SOD1 . . . . C NA D D 3 G229T D77Y 3 0
21 33039603 SOD1 0.0009 0.00078 1.11  103 rs80265967 N B B N 4 A272C D91A 3 0
21 33039636 SOD1 . . . . C NA D D 4 A305G D102G 1 0
21 33039650 SOD1 . . . . C NA D D 4 C319T L107F 1 0
21 33039666 SOD1 . . . . N NA NA D 4 G335A C112Y 1 0
21 33039672 SOD1 . 0.00026 . rs121912441 C NA D D 4 T341C I114T 5 0
21 33040829 SOD1 . . . . C NA NA D 5 A403G S135G 1 0
22 29885016 NEFH 0.04 0.09 0.069 rs59371099 C B NA D 4 G1387A E463K 173 109
22 29885473 NEFH 0.17 0.23 0.182 rs5763269 C D D D 4 C1844T P615L 414 205
22 29885997 NEFH . . 8.78  104 rs59551486 . . . . 4 2368_2370
delAAG
K790del 1 2
22 29886043 NEFH 0.12 0.17 0.153 rs165602 C D NA N 4 A2414C E805A 309 152
X 56591796 UBQLN2 . . . . C B NA N 1 C1490A P497H 1 0
The references for these variants are found in Supplementary Table 3.
1000g = 1000 Genomes project; prediction scores: C = conserved; D = damaging; B = benign; N = not conserved; NA = not applicable.
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Under this interpretation, 109 of 1125 cases were predicted
to carry a pathological expansion of the C9orf72 gene,
19 cases with a likely causal SOD1 mutation, 14 within
TARDBP and nine with a FUS variant.
Burden of rare variants
SKAT analysis showed an increased number of rare vari-
ants in cases compared to controls (P = 0.003). As this may
be solely due to known pathogenic variants, those previ-
ously reported in ALS were excluded, regardless of putative
pathogenicity, and SKAT was repeated. The result was still
signiﬁcant (P = 0.01). The burden lay primarily in the UTR
and intronic regions rather than exons. We therefore tested
introns and UTRs (P = 0.04) independently of exons
[P = 0.1 (synonymous) and P = 0.1 (non-synonymous)].
Additionally, there were more rare variants in UTRs than
in introns in patients but we did not have the statistical
power to investigate this in detail (see Supplementary
Table 5 for full results).
Oligogenic analysis
A binomial test restricted to exonic variants previously
published in ALS did not show an excess of patients with
two mutations (P = 0.4; see Supplementary Table 4 for
variant references). Unrestricted testing of exons and adja-
cent regions for C9orf72, SOD1, TARDBP, FUS, ANG,
ALS2, VCP, OPTN, NEFH and UBQLN2 showed 11 pa-
tients with more than one mutation, signiﬁcantly higher
than expected by chance based on the mutation rates in
cases and controls (P = 0.001; see Supplementary Table 6
for variant and patient information).
Common variation in amyotrophic
lateral sclerosis
The genes PON1–3 and VEGFA have both been reported
as potential risk factors for ALS. We selected 20 loci of
common variation within these genes to analyse but did
not ﬁnd any signiﬁcant differences in SNP frequencies be-
tween controls and cases and, in fact, some reported im-
portant SNPs were present at a higher rate in controls than
in cases (Supplementary Table 7). The frequencies in our
cohort were higher than those observed in the ExAC
database.
Discussion
We analysed 24 ALS genes in 1736 subjects. We detected
55 variants previously published in ALS or other diseases
and 845 rare variants of uncertain signiﬁcance, with a
higher burden of variants in cases, an excess in the untrans-
lated regions and introns, and oligogenic inheritance in 1%
of patients. A limitation of this study is its focus on a spe-
ciﬁc set of ALS genes rather than being a truly unbiased
survey of the exome or genome, but this has allowed us to
test speciﬁc hypotheses. Cases with likely pathogenic
SOD1, TARDBP and FUS mutations are more likely to
report a family history while those with a C9orf72 expan-
sion are more commonly sporadic and bulbar onset.
Untranslated region analysis in
amyotrophic lateral sclerosis
The UTRs of genes are often ignored in genetic studies of
disease, partly because of the difﬁculty in interpreting ﬁnd-
ings. We included UTRs to address this lack of knowledge
targeting SOD1, TARDBP, FUS, OPTN, VCP and
UBQLN2, as well as partial coverage in the remaining
genes. SKAT analysis revealed a signiﬁcant excess of rare
variants in patients in the UTRs and introns, and inspection
of the data suggested that the UTRs contained most of this
burden. Previous studies have also suggested this effect
(Fig. 1). An Italian study of 420 people with ALS and
480 controls found non-coding mutations in the 3’UTR of
FUS in patients, with four unique rare variants in ﬁve indi-
viduals and no rare variants in controls (Sabatelli et al.,
2013). Three variants were studied further in primary ﬁbro-
blast cultures (c.*59G4A, c.*108C4T and c.*110G4A).
The UTR variants and a known pathogenic exonic FUS
variant all cause a mislocalization of the FUS protein, an
effect not seen in the other patients or controls. Similarly,
the c.*48G4A variant, found in two subjects with a rap-
idly progressive form of ALS, increase FUS expression dra-
matically (Dini Modigliani et al., 2014); overexpression of
wild-type FUS causes an ALS-like syndrome in mice
(Mitchell et al., 2013). The 3’UTR of FUS is known to be
involved in a feedback loop for its own expression via the
alternative splicing of exon 7 (Zhou et al., 2013). On the
other hand, FUS-knockout mice exhibit abnormalities but
not ALS (Kino et al., 2015), and the ExAC database
shows no loss of function FUS variants in any of the
58787 individuals sequenced despite a statistical expect-
ation of there being 28.6. This number is calculated using
the mutation rate across the whole genome to produce a per
gene probability of each type of mutation. Factoring in
coverage metrics, an expected number of variants, in this
case 28.6, can be obtained for the number of individuals
sequenced (Lek et al., 2015). These studies combined sug-
gest that tight control of FUS expression is necessary in
humans (Dini Modigliani et al., 2014).
There are similar ﬁndings for TARDBP: a 3’ UTR vari-
ant c.*2076G4A found in two affected members of a
family with ALS and FTD (Gitcho et al., 2009), doubled
TARDBP RNA expression and was not present in 982
controls. Like FUS, TARDBP also regulates its own expres-
sion through the 3’UTR (Ayala et al., 2011), although this
is achieved through RNA instability rather than splicing.
Again, as with FUS, there are no loss-of-function variants
in TARDBP in the ExAC database when 11.8 are expected.
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These ﬁndings suggest variants in the UTRs of FUS and
TARDBP have a role in ALS pathogenesis (Fig. 2).
Oligogenic basis of amyotrophic
lateral sclerosis
We implemented a binominal test based on the probability
distribution of mutations in both cases and controls to
identify a greater than chance observation of combined
pathogenic mutations. There was no excess of oligogenic
ALS when the analysis was restricted to previously reported
ALS variants, but previous studies have been unrestricted,
examining all rare variants in targeted genes (van
Blitterswijk et al., 2012). Performing this analysis, 1% of
our patients had two mutations, signiﬁcantly higher than
expected based on known mutation rates. Most had
C9orf72 repeat expansion combined with another mutation
(e.g. VCP R155H or TARDBP A321V; Supplementary
Table 6). A single control also had two mutations,
P372R in ALS2 and A90V in TARDBP. ALS2 pathogen-
icity has only been observed in homozygotes, and this
individual was heterozygous. Furthermore, the TARDBP
variant has been previously identiﬁed in controls and has
unclear status, although it is associated with abnormal lo-
calization and aggregation of TARDBP (Guerreiro et al.,
2008; Winton et al., 2008).
What constitutes a pathogenic combination of mutations
is debatable as some variants are of uncertain signiﬁcance
(Richards et al., 2015), and the combination of a patho-
genic variant with one of uncertain signiﬁcance has been
considered oligogenic inheritance by some (Nakamura
et al., 2016). Similarly, variation in ANG or NEFH is gen-
erally considered a weak contributor to ALS risk, and mis-
sense variants in SPG11 are often benign unless resulting in
loss of function. We ﬁnd oligogenic inheritance even when
these genes are excluded from the analysis. Notably, one of
our controls harboured a loss-of-function mutation in
SPG11. Allowing a looser deﬁnition of oligogenic inherit-
ance, oligogenic ALS is reported in 1.6% of cases (4% in
familial and 1.3% in sporadic ALS) (Kenna et al., 2013).
Oligogenic ALS involving the convergence of two ALS
families has also been observed, with the proband carrying
Figure 2 Schematic representation of the UTRs of TARDBP and FUS and the variants found in this study within cases (blue) and
controls (black) in these regions. Variants within the 5’UTR are preceded with a minus while those contained in the 3’UTR are headed by an
asterisk. This includes variants previously published in ALS marked in red (Supplementary Table 8).
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a pathogenic TARDBP variant and C9orf72 repeat expan-
sion (Chio` et al., 2012). This appears to be associated with
a more severe phenotype and an earlier age of onset. In
another study of 391 cases, 3.8% had more than one mu-
tation and an earlier age of onset by 10 years (Cady et al.,
2015).
Common variation
Several previous studies have examined common variations
in VEGFA and PON1–3, which are inconsistently asso-
ciated with ALS (Lambrechts et al., 2003; Wills et al.,
2009). We characterized 20 loci in patients and controls
to ﬁnd no relationship with ALS, but this may be due to
low call rates in patients for these particular genes
(Supplementary Table 7). For example, rs7493 and
rs12026 were associated with controls, but only 95 cases
had adequate data. Furthermore, 14 of the 20 tested loci
were at higher frequencies in our controls than in the ExAC
and 1000 Genomes databases, with six being considerably
higher. This highlights the importance of collecting ad-
equate controls for each study rather than solely relying
on public data.
The sole known pathogenic DAO variant R199W has
been reported in two studies and correlates with survival
(Mitchell et al., 2010; Cirulli et al., 2015). We identiﬁed
two subjects with sporadic ALS who harboured a different
variant at the same codon: R199Q, and another alteration
two amino acids away: Q201R. Both of these DAO mu-
tants are predicted to be damaging by PhyloP, SIFT,
PolyPhen and LRT, and were not found in our control
samples.
Our large-scale sequencing study in ALS has identiﬁed a
number of rare variations, many novel, and shown that the
UTR of TARDBP and FUS are potentially important in the
pathogenesis of ALS. We have also provided further sup-
port for oligogenic inheritance of ALS in a proportion of
cases.
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